Barinthus Bio’s HPV Immunotherapy Fails to Demonstrate Statistically Significant Efficacy in Early Study

1. Barinthus Biotherapeutics' investigational immunotherapy, VTP-200, did not show a statistically significant benefit in clearing out human papillomavirus (HPV) infection.
2. The early study was conducted with 108 participants who had persistent high-risk HPV infection and low-grade cervical lesions.
3. The study was randomized, with participants receiving either VTP-200 or a placebo.
4. The results of the study were reported on April 19, 2024.
5. Despite the underwhelming efficacy, the immunotherapy was found to be safe.